LBF20203PG01
LipidBank Top (トップ) |
Fatty acid (脂肪酸) |
Glycerolipid (グリセロ脂質) |
Sphingolipid (スフィンゴ脂質) |
Journals (雑誌一覧) |
How to edit (ページの書き方) |
IDs and Links | |
---|---|
LipidBank | XPR1706 |
LipidMaps | LMFA03010143 |
CAS | |
KEGG | {{{KEGG}}} |
KNApSAcK | {{{KNApSAcK}}} |
mol | LBF20203PG01 |
δ17-Prostaglandin E1 | |
---|---|
Structural Information | |
9-Oxo- (11α,15S) -dihydroxy-prosta- (trans-13,cis-17) -dien-1-oic acid | |
| |
Formula | C20H32O5 |
Exact Mass | 352.224974134 |
Average Mass | 352.46508 |
SMILES | C(=CC[C@@H](O)C=C[C@H]([C@H]1CCCCCCC(O)=O)[C@@H](CC1=O)O)CC |
Physicochemical Information | |
Delta ^{17}-PGE1 is produced by the cyclooxigenase metabolism of omega -3 arachidonic acid. | |
Delta ^{17}-PGE1 is about half as potent as PGE1 as an inhibitor of ADP-induced aggregation of rabbbit PRP. Kobzar_G et al. In humanPRP, Delta ^{17}-PGE1 is a more potent antiplatelet agonist than PGE1. | |
Spectral Information | |
Mass Spectra | |
UV Spectra | |
IR Spectra | |
NMR Spectra | |
Other Spectra | |
Chromatograms |
Reported Metabolites, References | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|
|